vs

Side-by-side financial comparison of Eos Energy Enterprises, Inc. (EOSE) and Health Catalyst, Inc. (HCAT). Click either name above to swap in a different company.

Health Catalyst, Inc. is the larger business by last-quarter revenue ($74.7M vs $58.0M, roughly 1.3× Eos Energy Enterprises, Inc.). Health Catalyst, Inc. runs the higher net margin — -121.9% vs -207.7%, a 85.8% gap on every dollar of revenue. On growth, Eos Energy Enterprises, Inc. posted the faster year-over-year revenue change (699.6% vs -6.2%). Health Catalyst, Inc. produced more free cash flow last quarter ($9.6M vs $-75.2M).

Eos Energy Enterprises, Inc. is an energy storage solutions provider that designs, produces and deploys safe long-duration zinc-based battery systems. It serves utility, commercial, industrial and microgrid customers across North America, Europe and Asia, supporting grid stability and renewable energy integration.

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida, United States. The company develops medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS). The drug is referred to under the trade name Firdapse, which was approved by the FDA for approved use in children 6 years and older with LEMS in addition to the prior approval for use in adults with LEMS on November 28, 2018. Fir...

EOSE vs HCAT — Head-to-Head

Bigger by revenue
HCAT
HCAT
1.3× larger
HCAT
$74.7M
$58.0M
EOSE
Growing faster (revenue YoY)
EOSE
EOSE
+705.8% gap
EOSE
699.6%
-6.2%
HCAT
Higher net margin
HCAT
HCAT
85.8% more per $
HCAT
-121.9%
-207.7%
EOSE
More free cash flow
HCAT
HCAT
$84.9M more FCF
HCAT
$9.6M
$-75.2M
EOSE

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
EOSE
EOSE
HCAT
HCAT
Revenue
$58.0M
$74.7M
Net Profit
$-120.5M
$-91.0M
Gross Margin
-93.8%
Operating Margin
-140.1%
-115.3%
Net Margin
-207.7%
-121.9%
Revenue YoY
699.6%
-6.2%
Net Profit YoY
55.1%
-340.3%
EPS (diluted)
$-0.53
$-1.29

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EOSE
EOSE
HCAT
HCAT
Q4 25
$58.0M
$74.7M
Q3 25
$30.5M
$76.3M
Q2 25
$15.2M
$80.7M
Q1 25
$10.5M
$79.4M
Q4 24
$7.3M
$79.6M
Q3 24
$76.4M
Q2 24
$75.9M
Q1 24
$74.7M
Net Profit
EOSE
EOSE
HCAT
HCAT
Q4 25
$-120.5M
$-91.0M
Q3 25
$-641.4M
$-22.2M
Q2 25
$-222.9M
$-41.0M
Q1 25
$15.1M
$-23.7M
Q4 24
$-268.1M
$-20.7M
Q3 24
$-14.7M
Q2 24
$-13.5M
Q1 24
$-20.6M
Gross Margin
EOSE
EOSE
HCAT
HCAT
Q4 25
-93.8%
Q3 25
-111.2%
52.6%
Q2 25
-203.2%
Q1 25
-234.7%
Q4 24
-324.0%
Q3 24
47.5%
Q2 24
Q1 24
Operating Margin
EOSE
EOSE
HCAT
HCAT
Q4 25
-140.1%
-115.3%
Q3 25
-200.6%
-22.9%
Q2 25
-419.1%
-46.0%
Q1 25
-506.2%
-25.4%
Q4 24
-712.8%
-22.0%
Q3 24
-17.9%
Q2 24
-20.8%
Q1 24
-30.5%
Net Margin
EOSE
EOSE
HCAT
HCAT
Q4 25
-207.7%
-121.9%
Q3 25
-2102.1%
-29.1%
Q2 25
-1463.2%
-50.8%
Q1 25
144.7%
-29.9%
Q4 24
-3696.7%
-26.0%
Q3 24
-19.3%
Q2 24
-17.8%
Q1 24
-27.6%
EPS (diluted)
EOSE
EOSE
HCAT
HCAT
Q4 25
$-0.53
$-1.29
Q3 25
$-4.91
$-0.32
Q2 25
$-1.05
$-0.59
Q1 25
$-0.20
$-0.35
Q4 24
$-2.30
$-0.33
Q3 24
$-0.24
Q2 24
$-0.23
Q1 24
$-0.35

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EOSE
EOSE
HCAT
HCAT
Cash + ST InvestmentsLiquidity on hand
$568.0M
$95.7M
Total DebtLower is stronger
$813.3M
$153.3M
Stockholders' EquityBook value
$-2.2B
$245.8M
Total Assets
$885.2M
$502.6M
Debt / EquityLower = less leverage
0.62×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EOSE
EOSE
HCAT
HCAT
Q4 25
$568.0M
$95.7M
Q3 25
$58.7M
$91.5M
Q2 25
$120.2M
$97.3M
Q1 25
$82.6M
$342.0M
Q4 24
$74.3M
$392.0M
Q3 24
$387.3M
Q2 24
$308.3M
Q1 24
$327.8M
Total Debt
EOSE
EOSE
HCAT
HCAT
Q4 25
$813.3M
$153.3M
Q3 25
$448.5M
$153.1M
Q2 25
$445.3M
$153.0M
Q1 25
$325.5M
$382.9M
Q4 24
$316.9M
$382.4M
Q3 24
$345.0M
Q2 24
Q1 24
Stockholders' Equity
EOSE
EOSE
HCAT
HCAT
Q4 25
$-2.2B
$245.8M
Q3 25
$-2.3B
$331.9M
Q2 25
$-1.1B
$347.5M
Q1 25
$-942.2M
$376.8M
Q4 24
$-1.1B
$365.2M
Q3 24
$355.0M
Q2 24
$357.0M
Q1 24
$357.2M
Total Assets
EOSE
EOSE
HCAT
HCAT
Q4 25
$885.2M
$502.6M
Q3 25
$328.2M
$587.1M
Q2 25
$361.0M
$616.2M
Q1 25
$263.3M
$891.5M
Q4 24
$260.3M
$858.9M
Q3 24
$813.0M
Q2 24
$691.7M
Q1 24
$695.1M
Debt / Equity
EOSE
EOSE
HCAT
HCAT
Q4 25
0.62×
Q3 25
0.46×
Q2 25
0.44×
Q1 25
1.02×
Q4 24
1.05×
Q3 24
0.97×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EOSE
EOSE
HCAT
HCAT
Operating Cash FlowLast quarter
$-50.3M
$9.9M
Free Cash FlowOCF − Capex
$-75.2M
$9.6M
FCF MarginFCF / Revenue
-129.7%
12.9%
Capex IntensityCapex / Revenue
43.1%
0.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-265.0M
$-697.0K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EOSE
EOSE
HCAT
HCAT
Q4 25
$-50.3M
$9.9M
Q3 25
$-65.9M
$-464.0K
Q2 25
$-66.1M
$-9.0M
Q1 25
$-28.9M
$280.0K
Q4 24
$-42.7M
$-3.5M
Q3 24
$6.2M
Q2 24
$1.6M
Q1 24
$10.3M
Free Cash Flow
EOSE
EOSE
HCAT
HCAT
Q4 25
$-75.2M
$9.6M
Q3 25
$-82.7M
$-719.0K
Q2 25
$-73.2M
$-9.2M
Q1 25
$-33.8M
$-390.0K
Q4 24
$-55.8M
$-3.9M
Q3 24
$5.5M
Q2 24
$1.3M
Q1 24
$10.1M
FCF Margin
EOSE
EOSE
HCAT
HCAT
Q4 25
-129.7%
12.9%
Q3 25
-271.1%
-0.9%
Q2 25
-480.2%
-11.4%
Q1 25
-323.6%
-0.5%
Q4 24
-769.1%
-4.9%
Q3 24
7.2%
Q2 24
1.7%
Q1 24
13.5%
Capex Intensity
EOSE
EOSE
HCAT
HCAT
Q4 25
43.1%
0.4%
Q3 25
55.2%
0.3%
Q2 25
46.2%
0.3%
Q1 25
47.0%
0.8%
Q4 24
180.6%
0.5%
Q3 24
0.9%
Q2 24
0.4%
Q1 24
0.3%
Cash Conversion
EOSE
EOSE
HCAT
HCAT
Q4 25
Q3 25
Q2 25
Q1 25
-1.91×
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

EOSE
EOSE

Segment breakdown not available.

HCAT
HCAT

Recurring Technology$51.9M69%
Professional Services$22.8M31%

Related Comparisons